baricitinib vs Ruxolitinib (Opzelura)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: JAK1/2 · full Atopic Dermatitis pipeline

baricitinib · Olumiant

Marketed by Eli Lilly and partners

Phase 3 in Atopic Dermatitissmall molecule
Reliable signal

NCT03334396 · Phase 3 · completed

This was a large, randomized, double-blind, placebo-controlled trial of 660 participants. The primary clinical endpoint was met for both 2 mg and 4 mg baricitinib: 11.4% and 16.8% achieved the specified IGA response versus 4.8% with placebo, with statistically significant comparisons.

Next expected readout: May 2030 · NCT07262983 (registry estimate)

Reported efficacy

Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib) (16 Weeks): Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib) (16 Weeks): 2mg Baricitinib 10.6% | 4mg Baricitinib 13.8% vs Placebo 4.5% (met)

Result source: NCT03334422

Ruxolitinib (Opzelura)

Marketed by Incyte and partners

Approved in Atopic Dermatitissmall molecule
Reliable signal

NCT03745638 · Phase 3 · completed

This was a randomized, quadruple-blinded, vehicle-controlled Phase 3 trial with 631 participants, comparing two doses of ruxolitinib cream against placebo. The primary endpoint was a clinician-assessed measure of disease severity (IGA treatment success at Week 8), and the comparison was met decisively: both ruxolitinib groups achieved significantly higher response rates than vehicle (50.0% and 53.8% vs 15.1%, each p<0.0001). The sample size was adequate, treatment assignment was concealed, and the hard clinical endpoint clearly favored active treatment.

Next expected readout: August 2027 · NCT07661979 (registry estimate)

Reported efficacy

Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): VC Period: Ruxolitinib 0.75% Cream BID 50% (95% CI 43.7 to 56.3) | VC Period: Ruxolitinib 1.5% Cream BID 53.8% (95% CI 47.4 to 60) vs VC Period: Vehicle Cream BID 15.1% (95% CI 9.3 to 22.5) (met)

Result source: NCT03745638

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointbaricitinibRuxolitinib (Opzelura)
EASI-7531.5% vs 17.2%+14.3 vs placebo4 mg · wk 16 · n 92NCT03428100
65 other results
  • 27.6% vs 17.2% 2 mg · wk 16 · n 185 · Phase 3 · primary NCT03428100
  • 29.5% vs 8.2% 2 mg · wk 16 · n 146 · Phase 3 · primary NCT03435081
  • 39.8% vs 54.3% 4 mg · wk 104 · n 264 · Phase 3 · secondary NCT03334435
  • 73.8% vs 43.5% 4 mg · wk 104 · n 84 · Phase 3 · secondary NCT03334435
  • 37% vs 26.9% 4 mg · wk 52 · n 92 · Phase 3 · secondary NCT03428100
  • 25% vs 17.2% 4 mg · wk 24 · n 92 · Phase 3 · secondary NCT03428100
  • 47.7% vs 22.9% 4 mg · wk 16 · n 111 · Phase 3 · secondary NCT03733301
  • 40.9% vs 54.3% 2 mg · wk 104 · n 193 · Phase 3 · secondary NCT03334435
  • 30.3% vs 26.9% 2 mg · wk 52 · n 185 · Phase 3 · secondary NCT03428100
  • 27.6% vs 17.2% 2 mg · wk 24 · n 185 · Phase 3 · secondary NCT03428100
  • 12.9% vs 8.2% 1 mg · wk 16 · n 147 · Phase 3 · secondary NCT03435081
  • 76.7% vs 55.1% 4 mg · wk 104 · n 43 · Phase 3 · secondary NCT03334435
  • 79.8% vs 44.6% 4 mg · wk 68 · n 84 · Phase 3 · secondary NCT03334435
  • 93% vs 63.3% 4 mg · wk 68 · n 43 · Phase 3 · secondary NCT03334435
  • 51.4% vs 38.5% 4 mg · wk 52 · n 70 · Phase 3 · secondary NCT03334435
  • 42.9% vs 38.2% 4 mg · wk 52 · n 63 · Phase 3 · secondary NCT03334435
  • 51.4% vs 44.2% 4 mg · wk 36 · n 70 · Phase 3 · secondary NCT03334435
  • 44.4% vs 47.1% 4 mg · wk 36 · n 63 · Phase 3 · secondary NCT03334435
  • 24.8% vs 8.8% 4 mg · wk 16 · n 125 · Phase 3 · secondary NCT03334396
  • 21.1% vs 6.1% 4 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334422
  • 61.5% vs 71.4% 4 mg · wk 68 · n 39 · Phase 3 · secondary NCT03334435
  • 64.3% vs 42.3% 4 mg · wk 16 · n 70 · Phase 3 · secondary NCT03334435
  • 55.6% vs 55.9% 4 mg · wk 16 · n 63 · Phase 3 · secondary NCT03334435
  • 58.3% vs 43.5% 2 mg · wk 104 · n 84 · Phase 3 · secondary NCT03334435
  • 72.8% vs 43.5% 2 mg · wk 104 · n 92 · Phase 3 · secondary NCT03334435
  • 74.4% vs 55.1% 2 mg · wk 104 · n 43 · Phase 3 · secondary NCT03334435
  • 83.3% vs 55.1% 2 mg · wk 104 · n 48 · Phase 3 · secondary NCT03334435
  • 58.3% vs 44.6% 2 mg · wk 68 · n 84 · Phase 3 · secondary NCT03334435
  • 73.9% vs 44.6% 2 mg · wk 68 · n 92 · Phase 3 · secondary NCT03334435
  • 68.2% vs 72.4% 2 mg · wk 104 · n 22 · Phase 3 · secondary NCT03428100
  • 76.7% vs 63.3% 2 mg · wk 68 · n 43 · Phase 3 · secondary NCT03334435
  • 83.3% vs 63.3% 2 mg · wk 68 · n 48 · Phase 3 · secondary NCT03334435
  • 53.2% vs 71.4% 2 mg · wk 68 · n 47 · Phase 3 · secondary NCT03334435
  • 55.1% vs 71.4% 2 mg · wk 68 · n 49 · Phase 3 · secondary NCT03334435
  • 64.8% vs 38.5% 2 mg · wk 52 · n 54 · Phase 3 · secondary NCT03334435
  • 52.8% vs 38.2% 2 mg · wk 52 · n 53 · Phase 3 · secondary NCT03334435
  • 74.1% vs 44.2% 2 mg · wk 36 · n 54 · Phase 3 · secondary NCT03334435
  • 47.2% vs 47.1% 2 mg · wk 36 · n 53 · Phase 3 · secondary NCT03334435
  • 18.7% vs 8.8% 2 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334396
  • 17.9% vs 6.1% 2 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334422
  • 70.4% vs 42.3% 2 mg · wk 16 · n 54 · Phase 3 · secondary NCT03334435
  • 67.9% vs 55.9% 2 mg · wk 16 · n 53 · Phase 3 · secondary NCT03334435
  • 43.1% vs 22.9% 2 mg · wk 16 · n 109 · Phase 3 · secondary NCT03733301
  • 58.2% vs 43.5% 1 mg · wk 104 · n 91 · Phase 3 · secondary NCT03334435
  • 63.6% vs 62.1% 2 mg · wk 68 · n 22 · Phase 3 · secondary NCT03428100
  • 79.2% vs 55.1% 1 mg · wk 104 · n 48 · Phase 3 · secondary NCT03334435
  • 65.6% vs 54.3% 1 mg · wk 104 · n 32 · Phase 3 · secondary NCT03334435
  • 70.6% vs 72.4% 1 mg · wk 104 · n 34 · Phase 3 · secondary NCT03428100
  • 69.2% vs 44.6% 1 mg · wk 68 · n 91 · Phase 3 · secondary NCT03334435
  • 89.6% vs 63.3% 1 mg · wk 68 · n 48 · Phase 3 · secondary NCT03334435
  • 44.4% vs 71.4% 1 mg · wk 68 · n 45 · Phase 3 · secondary NCT03334435
  • 76.5% vs 62.1% 1 mg · wk 68 · n 34 · Phase 3 · secondary NCT03428100
  • 51.1% vs 38.5% 1 mg · wk 52 · n 45 · Phase 3 · secondary NCT03334435
  • 33.3% vs 26.9% 1 mg · wk 52 · n 93 · Phase 3 · secondary NCT03428100
  • 46.7% vs 44.2% 1 mg · wk 36 · n 45 · Phase 3 · secondary NCT03334435
  • 30.1% vs 17.2% 1 mg · wk 24 · n 93 · Phase 3 · secondary NCT03428100
  • 17.3% vs 8.8% 1 mg · wk 16 · n 127 · Phase 3 · secondary NCT03334396
  • 12.8% vs 6.1% 1 mg · wk 16 · n 125 · Phase 3 · secondary NCT03334422
  • 62.2% vs 42.3% 1 mg · wk 16 · n 45 · Phase 3 · secondary NCT03334435
  • 22.6% vs 17.2% 1 mg · wk 16 · n 93 · Phase 3 · secondary NCT03428100
  • 32.2% vs 32% Low Dose · wk 16 · n 121 · Phase 3 · secondary NCT03952559
  • 40% vs 32% Medium Dose · wk 16 · n 120 · Phase 3 · secondary NCT03952559
  • 52.5% vs 32% High Dose · wk 16 · n 120 · Phase 3 · secondary NCT03952559
  • 85.7% vs 72.4% 4 mg · wk 104 · n 7 · Phase 3 · secondary NCT03428100
  • 57.1% vs 62.1% 4 mg · wk 68 · n 7 · Phase 3 · secondary NCT03428100
70% vs 18.5%+51.5 vs placebo1.5% · wk 8 · n 160NCT06238817
21 other results
  • 56% vs 24.6% 0.75% Cream BID · wk 8 · n 252 · Phase 3 · secondary NCT03745638
  • 62.1% vs 24.6% 1.5% Cream BID · wk 8 · n 253 · Phase 3 · secondary NCT03745638
  • 51.5% vs 14.4% 0.75% cream BID · wk 8 · n 231 · Phase 3 · secondary NCT03745651
  • 61.8% vs 14.4% 1.5% cream BID · wk 8 · n 228 · Phase 3 · secondary NCT03745651
  • 51.5% vs 15.4% 0.75% Cream BID · wk 8 · n 134 · Phase 3 · secondary NCT04921969
  • 67.2% vs 15.4% 1.5% Cream BID · wk 8 · n 131 · Phase 3 · secondary NCT04921969
  • 51.6% vs 14.3% 0.75% Cream BID · wk 4 · n 252 · Phase 3 · secondary NCT03745638
  • 58.5% vs 14.3% 1.5% Cream BID · wk 4 · n 253 · Phase 3 · secondary NCT03745638
  • 42% vs 10.2% 0.75% cream BID · wk 4 · n 231 · Phase 3 · secondary NCT03745651
  • 50.4% vs 10.2% 1.5% cream BID · wk 4 · n 228 · Phase 3 · secondary NCT03745651
  • 53% vs 12.3% 0.75% Cream BID · wk 4 · n 134 · Phase 3 · secondary NCT04921969
  • 62.6% vs 12.3% 1.5% Cream BID · wk 4 · n 131 · Phase 3 · secondary NCT04921969
  • 30.2% vs 5.6% 0.75% Cream BID · wk 2 · n 252 · Phase 3 · secondary NCT03745638
  • 36% vs 5.6% 1.5% Cream BID · wk 2 · n 253 · Phase 3 · secondary NCT03745638
  • 25.5% vs 4.2% 0.75% cream BID · wk 2 · n 231 · Phase 3 · secondary NCT03745651
  • 31.6% vs 4.2% 1.5% cream BID · wk 2 · n 228 · Phase 3 · secondary NCT03745651
  • 35.8% vs 6.2% 0.75% Cream BID · wk 2 · n 134 · Phase 3 · secondary NCT04921969
  • 43.5% vs 6.2% 1.5% Cream BID · wk 2 · n 131 · Phase 3 · secondary NCT04921969
  • 33.3% vs 35.3% 1.5% BID · wk 8 · n 48 · Phase 2 · secondary NCT05127421
  • 29.2% vs 33.3% 1.5% BID · wk 4 · n 48 · Phase 2 · secondary NCT05127421
  • 10.4% vs 5.6% 1.5% BID · wk 2 · n 48 · Phase 2 · secondary NCT05127421
IGA 0/1 with 2-point improvement13% vs 12.9%+0.1 vs placebo4 mg · wk 24 · n 92NCT03428100
5 other results
  • 21.7% vs 9.7% 4 mg · wk 16 · n 92 · Phase 3 · secondary NCT03428100
  • 18.9% vs 12.9% 2 mg · wk 24 · n 185 · Phase 3 · secondary NCT03428100
  • 15.1% vs 9.7% 2 mg · wk 16 · n 185 · Phase 3 · secondary NCT03428100
  • 20.4% vs 12.9% 1 mg · wk 24 · n 93 · Phase 3 · secondary NCT03428100
  • 12.9% vs 9.7% 1 mg · wk 16 · n 93 · Phase 3 · secondary NCT03428100
15.7% vs 9.6%+6.1 vs placebo0.15% QD · wk 8 · n 51NCT03011892
11 other results
  • 31.4% vs 9.6% 0.5% QD · wk 8 · n 51 · Phase 2 · secondary NCT03011892
  • 30.8% vs 9.6% 1.5% QD · wk 8 · n 52 · Phase 2 · secondary NCT03011892
  • 48% vs 9.6% 1.5% BID · wk 8 · n 50 · Phase 2 · secondary NCT03011892
  • 9.8% vs 7.7% 0.15% QD · wk 4 · n 51 · Phase 2 · secondary NCT03011892
  • 13.7% vs 7.7% 0.5% QD · wk 4 · n 51 · Phase 2 · secondary NCT03011892
  • 21.2% vs 7.7% 1.5% QD · wk 4 · n 52 · Phase 2 · secondary NCT03011892
  • 38% vs 7.7% 1.5% BID · wk 4 · n 50 · Phase 2 · secondary NCT03011892
  • 5.9% vs 1.9% 0.15% QD · wk 2 · n 51 · Phase 2 · secondary NCT03011892
  • 4.1% vs 1.9% 0.5% QD · wk 2 · n 51 · Phase 2 · secondary NCT03011892
  • 13.5% vs 1.9% 1.5% QD · wk 2 · n 52 · Phase 2 · secondary NCT03011892
  • 8% vs 1.9% 1.5% BID · wk 2 · n 50 · Phase 2 · secondary NCT03011892
EASI-9016% vs 4.8%+11.2 vs placebo4 mg · wk 16 · n 125NCT03334396
15 other results
  • 13% vs 2.5% 4 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334422
  • 14.1% vs 6.5% 4 mg · wk 16 · n 92 · Phase 3 · secondary NCT03428100
  • 24.3% vs 13.8% 4 mg · wk 16 · n 111 · Phase 3 · secondary NCT03733301
  • 10.6% vs 4.8% 2 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334396
  • 8.9% vs 2.5% 2 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334422
  • 10.3% vs 6.5% 2 mg · wk 16 · n 185 · Phase 3 · secondary NCT03428100
  • 20.5% vs 3.4% 2 mg · wk 16 · n 146 · Phase 3 · secondary NCT03435081
  • 16.5% vs 13.8% 2 mg · wk 16 · n 109 · Phase 3 · secondary NCT03733301
  • 8.7% vs 4.8% 1 mg · wk 16 · n 127 · Phase 3 · secondary NCT03334396
  • 6.4% vs 2.5% 1 mg · wk 16 · n 125 · Phase 3 · secondary NCT03334422
  • 8.6% vs 6.5% 1 mg · wk 16 · n 93 · Phase 3 · secondary NCT03428100
  • 7.5% vs 3.4% 1 mg · wk 16 · n 147 · Phase 3 · secondary NCT03435081
  • 11.6% vs 12.3% Low Dose · wk 16 · n 121 · Phase 3 · secondary NCT03952559
  • 21.7% vs 12.3% Medium Dose · wk 16 · n 120 · Phase 3 · secondary NCT03952559
  • 30% vs 12.3% High Dose · wk 16 · n 120 · Phase 3 · secondary NCT03952559
38.1% vs 9.5%+28.6 vs placebo0.75% Cream BID · wk 8 · n 252NCT03745638
11 other results
  • 44.3% vs 9.5% 1.5% Cream BID · wk 8 · n 253 · Phase 3 · secondary NCT03745638
  • 35.1% vs 4.2% 0.75% cream BID · wk 8 · n 231 · Phase 3 · secondary NCT03745651
  • 43.4% vs 4.2% 1.5% cream BID · wk 8 · n 228 · Phase 3 · secondary NCT03745651
  • 30.6% vs 4% 0.75% Cream BID · wk 4 · n 252 · Phase 3 · secondary NCT03745638
  • 36.4% vs 4% 1.5% Cream BID · wk 4 · n 253 · Phase 3 · secondary NCT03745638
  • 25.5% vs 2.5% 0.75% cream BID · wk 4 · n 231 · Phase 3 · secondary NCT03745651
  • 32.5% vs 2.5% 1.5% cream BID · wk 4 · n 228 · Phase 3 · secondary NCT03745651
  • 12.7% vs 2.4% 0.75% Cream BID · wk 2 · n 252 · Phase 3 · secondary NCT03745638
  • 19.8% vs 2.4% 1.5% Cream BID · wk 2 · n 253 · Phase 3 · secondary NCT03745638
  • 10.8% vs 0.8% 0.75% cream BID · wk 2 · n 231 · Phase 3 · secondary NCT03745651
  • 15.8% vs 0.8% 1.5% cream BID · wk 2 · n 228 · Phase 3 · secondary NCT03745651
EASI, % change-59.4% vs -34.8%−24.5 vs placebo4 mg · wk 16 · n 70NCT03334396
12 other results
  • -54.9% vs -28.9% 4 mg · wk 16 · n 49 · Phase 3 · secondary NCT03334422
  • -63.3% vs -42.7% 4 mg · wk 16 · n 65 · Phase 3 · secondary NCT03428100
  • -67.2% vs -45.1% 4 mg · wk 16 · n 100 · Phase 3 · secondary NCT03733301
  • -51.9% vs -34.8% 2 mg · wk 16 · n 52 · Phase 3 · secondary NCT03334396
  • -56.0% vs -42.7% 2 mg · wk 16 · n 144 · Phase 3 · secondary NCT03428100
  • -54.8% vs -28.9% 2 mg · wk 16 · n 40 · Phase 3 · secondary NCT03334422
  • -54.4% vs -34.1% 2 mg · wk 16 · n 62 · Phase 3 · secondary NCT03435081
  • -58.2% vs -45.1% 2 mg · wk 16 · n 100 · Phase 3 · secondary NCT03733301
  • -48.2% vs -34.8% 1 mg · wk 16 · n 52 · Phase 3 · secondary NCT03334396
  • -41.7% vs -28.9% 1 mg · wk 16 · n 34 · Phase 3 · secondary NCT03334422
  • -60.3% vs -42.7% 1 mg · wk 16 · n 61 · Phase 3 · secondary NCT03428100
  • -46.7% vs -34.1% 1 mg · wk 16 · n 47 · Phase 3 · secondary NCT03435081
-71.0% vs -37.9%−33.1 vs placebo0.75% Cream BID · wk 8 · n 252NCT03745638
31 other results
  • -77.4% vs -37.9% 1.5% Cream BID · wk 8 · n 253 · Phase 3 · secondary NCT03745638
  • -73.4% vs -28.8% 0.75% cream BID · wk 8 · n 231 · Phase 3 · secondary NCT03745651
  • -74.8% vs -28.8% 1.5% cream BID · wk 8 · n 228 · Phase 3 · secondary NCT03745651
  • -68.0% vs -23.0% 0.75% Cream BID · wk 4 · n 252 · Phase 3 · secondary NCT03745638
  • -71.1% vs -23.0% 1.5% Cream BID · wk 4 · n 253 · Phase 3 · secondary NCT03745638
  • -65% vs -20.4% 0.75% cream BID · wk 4 · n 231 · Phase 3 · secondary NCT03745651
  • -66.3% vs -20.4% 1.5% cream BID · wk 4 · n 228 · Phase 3 · secondary NCT03745651
  • -51.8% vs -16.3% 0.75% Cream BID · wk 2 · n 252 · Phase 3 · secondary NCT03745638
  • -56.6% vs -16.3% 1.5% Cream BID · wk 2 · n 253 · Phase 3 · secondary NCT03745638
  • -45.9% vs -13.9% 0.75% cream BID · wk 2 · n 231 · Phase 3 · secondary NCT03745651
  • -49.1% vs -13.9% 1.5% cream BID · wk 2 · n 228 · Phase 3 · secondary NCT03745651
  • -71.6% vs -11.9% 1.5% BID · wk 4 · n 49 · Phase 2 · primary NCT03011892
  • -50.2% vs -21.9% 0.15% QD · wk 8 · n 51 · Phase 2 · secondary NCT03011892
  • -58.4% vs -21.9% 0.5% QD · wk 8 · n 51 · Phase 2 · secondary NCT03011892
  • -67.0% vs -21.9% 1.5% QD · wk 8 · n 52 · Phase 2 · secondary NCT03011892
  • -79.0% vs -21.9% 1.5% BID · wk 8 · n 50 · Phase 2 · secondary NCT03011892
  • -44.9% vs -11.9% 0.15% QD · wk 4 · n 47 · Phase 2 · secondary NCT03011892
  • -52.8% vs -11.9% 0.5% QD · wk 4 · n 47 · Phase 2 · secondary NCT03011892
  • -66.7% vs -11.9% 1.5% QD · wk 4 · n 49 · Phase 2 · secondary NCT03011892
  • -45.4% vs -15.5% 0.15% QD · wk 4 · n 47 · Phase 2 · secondary NCT03011892
  • -52.2% vs -15.5% 0.5% QD · wk 4 · n 47 · Phase 2 · secondary NCT03011892
  • -67% vs -15.5% 1.5% QD · wk 4 · n 49 · Phase 2 · secondary NCT03011892
  • -71.6% vs -15.5% 1.5% BID · wk 4 · n 49 · Phase 2 · secondary NCT03011892
  • -30.0% vs -4.8% 0.15% QD · wk 2 · n 51 · Phase 2 · secondary NCT03011892
  • -45.9% vs -4.8% 0.5% QD · wk 2 · n 51 · Phase 2 · secondary NCT03011892
  • -49.9% vs -4.8% 1.5% QD · wk 2 · n 52 · Phase 2 · secondary NCT03011892
  • -52.7% vs -4.8% 1.5% BID · wk 2 · n 50 · Phase 2 · secondary NCT03011892
  • -44.9% vs -59.5% 0.15% QD · wk 4 · n 47 · Phase 2 · secondary NCT03011892
  • -52.8% vs -59.5% 0.5% QD · wk 4 · n 47 · Phase 2 · secondary NCT03011892
  • -66.7% vs -59.5% 1.5% QD · wk 4 · n 49 · Phase 2 · secondary NCT03011892
  • -71.6% vs -59.5% 1.5% BID · wk 4 · n 49 · Phase 2 · secondary NCT03011892

EASI-75

baricitinib
31.5% vs 17.2%+14.3 vs placebo4 mg · wk 16 · n 92NCT03428100
65 other results
  • 27.6% vs 17.2% 2 mg · wk 16 · n 185 · Phase 3 · primary NCT03428100
  • 29.5% vs 8.2% 2 mg · wk 16 · n 146 · Phase 3 · primary NCT03435081
  • 39.8% vs 54.3% 4 mg · wk 104 · n 264 · Phase 3 · secondary NCT03334435
  • 73.8% vs 43.5% 4 mg · wk 104 · n 84 · Phase 3 · secondary NCT03334435
  • 37% vs 26.9% 4 mg · wk 52 · n 92 · Phase 3 · secondary NCT03428100
  • 25% vs 17.2% 4 mg · wk 24 · n 92 · Phase 3 · secondary NCT03428100
  • 47.7% vs 22.9% 4 mg · wk 16 · n 111 · Phase 3 · secondary NCT03733301
  • 40.9% vs 54.3% 2 mg · wk 104 · n 193 · Phase 3 · secondary NCT03334435
  • 30.3% vs 26.9% 2 mg · wk 52 · n 185 · Phase 3 · secondary NCT03428100
  • 27.6% vs 17.2% 2 mg · wk 24 · n 185 · Phase 3 · secondary NCT03428100
  • 12.9% vs 8.2% 1 mg · wk 16 · n 147 · Phase 3 · secondary NCT03435081
  • 76.7% vs 55.1% 4 mg · wk 104 · n 43 · Phase 3 · secondary NCT03334435
  • 79.8% vs 44.6% 4 mg · wk 68 · n 84 · Phase 3 · secondary NCT03334435
  • 93% vs 63.3% 4 mg · wk 68 · n 43 · Phase 3 · secondary NCT03334435
  • 51.4% vs 38.5% 4 mg · wk 52 · n 70 · Phase 3 · secondary NCT03334435
  • 42.9% vs 38.2% 4 mg · wk 52 · n 63 · Phase 3 · secondary NCT03334435
  • 51.4% vs 44.2% 4 mg · wk 36 · n 70 · Phase 3 · secondary NCT03334435
  • 44.4% vs 47.1% 4 mg · wk 36 · n 63 · Phase 3 · secondary NCT03334435
  • 24.8% vs 8.8% 4 mg · wk 16 · n 125 · Phase 3 · secondary NCT03334396
  • 21.1% vs 6.1% 4 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334422
  • 61.5% vs 71.4% 4 mg · wk 68 · n 39 · Phase 3 · secondary NCT03334435
  • 64.3% vs 42.3% 4 mg · wk 16 · n 70 · Phase 3 · secondary NCT03334435
  • 55.6% vs 55.9% 4 mg · wk 16 · n 63 · Phase 3 · secondary NCT03334435
  • 58.3% vs 43.5% 2 mg · wk 104 · n 84 · Phase 3 · secondary NCT03334435
  • 72.8% vs 43.5% 2 mg · wk 104 · n 92 · Phase 3 · secondary NCT03334435
  • 74.4% vs 55.1% 2 mg · wk 104 · n 43 · Phase 3 · secondary NCT03334435
  • 83.3% vs 55.1% 2 mg · wk 104 · n 48 · Phase 3 · secondary NCT03334435
  • 58.3% vs 44.6% 2 mg · wk 68 · n 84 · Phase 3 · secondary NCT03334435
  • 73.9% vs 44.6% 2 mg · wk 68 · n 92 · Phase 3 · secondary NCT03334435
  • 68.2% vs 72.4% 2 mg · wk 104 · n 22 · Phase 3 · secondary NCT03428100
  • 76.7% vs 63.3% 2 mg · wk 68 · n 43 · Phase 3 · secondary NCT03334435
  • 83.3% vs 63.3% 2 mg · wk 68 · n 48 · Phase 3 · secondary NCT03334435
  • 53.2% vs 71.4% 2 mg · wk 68 · n 47 · Phase 3 · secondary NCT03334435
  • 55.1% vs 71.4% 2 mg · wk 68 · n 49 · Phase 3 · secondary NCT03334435
  • 64.8% vs 38.5% 2 mg · wk 52 · n 54 · Phase 3 · secondary NCT03334435
  • 52.8% vs 38.2% 2 mg · wk 52 · n 53 · Phase 3 · secondary NCT03334435
  • 74.1% vs 44.2% 2 mg · wk 36 · n 54 · Phase 3 · secondary NCT03334435
  • 47.2% vs 47.1% 2 mg · wk 36 · n 53 · Phase 3 · secondary NCT03334435
  • 18.7% vs 8.8% 2 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334396
  • 17.9% vs 6.1% 2 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334422
  • 70.4% vs 42.3% 2 mg · wk 16 · n 54 · Phase 3 · secondary NCT03334435
  • 67.9% vs 55.9% 2 mg · wk 16 · n 53 · Phase 3 · secondary NCT03334435
  • 43.1% vs 22.9% 2 mg · wk 16 · n 109 · Phase 3 · secondary NCT03733301
  • 58.2% vs 43.5% 1 mg · wk 104 · n 91 · Phase 3 · secondary NCT03334435
  • 63.6% vs 62.1% 2 mg · wk 68 · n 22 · Phase 3 · secondary NCT03428100
  • 79.2% vs 55.1% 1 mg · wk 104 · n 48 · Phase 3 · secondary NCT03334435
  • 65.6% vs 54.3% 1 mg · wk 104 · n 32 · Phase 3 · secondary NCT03334435
  • 70.6% vs 72.4% 1 mg · wk 104 · n 34 · Phase 3 · secondary NCT03428100
  • 69.2% vs 44.6% 1 mg · wk 68 · n 91 · Phase 3 · secondary NCT03334435
  • 89.6% vs 63.3% 1 mg · wk 68 · n 48 · Phase 3 · secondary NCT03334435
  • 44.4% vs 71.4% 1 mg · wk 68 · n 45 · Phase 3 · secondary NCT03334435
  • 76.5% vs 62.1% 1 mg · wk 68 · n 34 · Phase 3 · secondary NCT03428100
  • 51.1% vs 38.5% 1 mg · wk 52 · n 45 · Phase 3 · secondary NCT03334435
  • 33.3% vs 26.9% 1 mg · wk 52 · n 93 · Phase 3 · secondary NCT03428100
  • 46.7% vs 44.2% 1 mg · wk 36 · n 45 · Phase 3 · secondary NCT03334435
  • 30.1% vs 17.2% 1 mg · wk 24 · n 93 · Phase 3 · secondary NCT03428100
  • 17.3% vs 8.8% 1 mg · wk 16 · n 127 · Phase 3 · secondary NCT03334396
  • 12.8% vs 6.1% 1 mg · wk 16 · n 125 · Phase 3 · secondary NCT03334422
  • 62.2% vs 42.3% 1 mg · wk 16 · n 45 · Phase 3 · secondary NCT03334435
  • 22.6% vs 17.2% 1 mg · wk 16 · n 93 · Phase 3 · secondary NCT03428100
  • 32.2% vs 32% Low Dose · wk 16 · n 121 · Phase 3 · secondary NCT03952559
  • 40% vs 32% Medium Dose · wk 16 · n 120 · Phase 3 · secondary NCT03952559
  • 52.5% vs 32% High Dose · wk 16 · n 120 · Phase 3 · secondary NCT03952559
  • 85.7% vs 72.4% 4 mg · wk 104 · n 7 · Phase 3 · secondary NCT03428100
  • 57.1% vs 62.1% 4 mg · wk 68 · n 7 · Phase 3 · secondary NCT03428100
Ruxolitinib (Opzelura)
70% vs 18.5%+51.5 vs placebo1.5% · wk 8 · n 160NCT06238817
21 other results
  • 56% vs 24.6% 0.75% Cream BID · wk 8 · n 252 · Phase 3 · secondary NCT03745638
  • 62.1% vs 24.6% 1.5% Cream BID · wk 8 · n 253 · Phase 3 · secondary NCT03745638
  • 51.5% vs 14.4% 0.75% cream BID · wk 8 · n 231 · Phase 3 · secondary NCT03745651
  • 61.8% vs 14.4% 1.5% cream BID · wk 8 · n 228 · Phase 3 · secondary NCT03745651
  • 51.5% vs 15.4% 0.75% Cream BID · wk 8 · n 134 · Phase 3 · secondary NCT04921969
  • 67.2% vs 15.4% 1.5% Cream BID · wk 8 · n 131 · Phase 3 · secondary NCT04921969
  • 51.6% vs 14.3% 0.75% Cream BID · wk 4 · n 252 · Phase 3 · secondary NCT03745638
  • 58.5% vs 14.3% 1.5% Cream BID · wk 4 · n 253 · Phase 3 · secondary NCT03745638
  • 42% vs 10.2% 0.75% cream BID · wk 4 · n 231 · Phase 3 · secondary NCT03745651
  • 50.4% vs 10.2% 1.5% cream BID · wk 4 · n 228 · Phase 3 · secondary NCT03745651
  • 53% vs 12.3% 0.75% Cream BID · wk 4 · n 134 · Phase 3 · secondary NCT04921969
  • 62.6% vs 12.3% 1.5% Cream BID · wk 4 · n 131 · Phase 3 · secondary NCT04921969
  • 30.2% vs 5.6% 0.75% Cream BID · wk 2 · n 252 · Phase 3 · secondary NCT03745638
  • 36% vs 5.6% 1.5% Cream BID · wk 2 · n 253 · Phase 3 · secondary NCT03745638
  • 25.5% vs 4.2% 0.75% cream BID · wk 2 · n 231 · Phase 3 · secondary NCT03745651
  • 31.6% vs 4.2% 1.5% cream BID · wk 2 · n 228 · Phase 3 · secondary NCT03745651
  • 35.8% vs 6.2% 0.75% Cream BID · wk 2 · n 134 · Phase 3 · secondary NCT04921969
  • 43.5% vs 6.2% 1.5% Cream BID · wk 2 · n 131 · Phase 3 · secondary NCT04921969
  • 33.3% vs 35.3% 1.5% BID · wk 8 · n 48 · Phase 2 · secondary NCT05127421
  • 29.2% vs 33.3% 1.5% BID · wk 4 · n 48 · Phase 2 · secondary NCT05127421
  • 10.4% vs 5.6% 1.5% BID · wk 2 · n 48 · Phase 2 · secondary NCT05127421

IGA 0/1 with 2-point improvement

baricitinib
13% vs 12.9%+0.1 vs placebo4 mg · wk 24 · n 92NCT03428100
5 other results
  • 21.7% vs 9.7% 4 mg · wk 16 · n 92 · Phase 3 · secondary NCT03428100
  • 18.9% vs 12.9% 2 mg · wk 24 · n 185 · Phase 3 · secondary NCT03428100
  • 15.1% vs 9.7% 2 mg · wk 16 · n 185 · Phase 3 · secondary NCT03428100
  • 20.4% vs 12.9% 1 mg · wk 24 · n 93 · Phase 3 · secondary NCT03428100
  • 12.9% vs 9.7% 1 mg · wk 16 · n 93 · Phase 3 · secondary NCT03428100
Ruxolitinib (Opzelura)
15.7% vs 9.6%+6.1 vs placebo0.15% QD · wk 8 · n 51NCT03011892
11 other results
  • 31.4% vs 9.6% 0.5% QD · wk 8 · n 51 · Phase 2 · secondary NCT03011892
  • 30.8% vs 9.6% 1.5% QD · wk 8 · n 52 · Phase 2 · secondary NCT03011892
  • 48% vs 9.6% 1.5% BID · wk 8 · n 50 · Phase 2 · secondary NCT03011892
  • 9.8% vs 7.7% 0.15% QD · wk 4 · n 51 · Phase 2 · secondary NCT03011892
  • 13.7% vs 7.7% 0.5% QD · wk 4 · n 51 · Phase 2 · secondary NCT03011892
  • 21.2% vs 7.7% 1.5% QD · wk 4 · n 52 · Phase 2 · secondary NCT03011892
  • 38% vs 7.7% 1.5% BID · wk 4 · n 50 · Phase 2 · secondary NCT03011892
  • 5.9% vs 1.9% 0.15% QD · wk 2 · n 51 · Phase 2 · secondary NCT03011892
  • 4.1% vs 1.9% 0.5% QD · wk 2 · n 51 · Phase 2 · secondary NCT03011892
  • 13.5% vs 1.9% 1.5% QD · wk 2 · n 52 · Phase 2 · secondary NCT03011892
  • 8% vs 1.9% 1.5% BID · wk 2 · n 50 · Phase 2 · secondary NCT03011892

EASI-90

baricitinib
16% vs 4.8%+11.2 vs placebo4 mg · wk 16 · n 125NCT03334396
15 other results
  • 13% vs 2.5% 4 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334422
  • 14.1% vs 6.5% 4 mg · wk 16 · n 92 · Phase 3 · secondary NCT03428100
  • 24.3% vs 13.8% 4 mg · wk 16 · n 111 · Phase 3 · secondary NCT03733301
  • 10.6% vs 4.8% 2 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334396
  • 8.9% vs 2.5% 2 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334422
  • 10.3% vs 6.5% 2 mg · wk 16 · n 185 · Phase 3 · secondary NCT03428100
  • 20.5% vs 3.4% 2 mg · wk 16 · n 146 · Phase 3 · secondary NCT03435081
  • 16.5% vs 13.8% 2 mg · wk 16 · n 109 · Phase 3 · secondary NCT03733301
  • 8.7% vs 4.8% 1 mg · wk 16 · n 127 · Phase 3 · secondary NCT03334396
  • 6.4% vs 2.5% 1 mg · wk 16 · n 125 · Phase 3 · secondary NCT03334422
  • 8.6% vs 6.5% 1 mg · wk 16 · n 93 · Phase 3 · secondary NCT03428100
  • 7.5% vs 3.4% 1 mg · wk 16 · n 147 · Phase 3 · secondary NCT03435081
  • 11.6% vs 12.3% Low Dose · wk 16 · n 121 · Phase 3 · secondary NCT03952559
  • 21.7% vs 12.3% Medium Dose · wk 16 · n 120 · Phase 3 · secondary NCT03952559
  • 30% vs 12.3% High Dose · wk 16 · n 120 · Phase 3 · secondary NCT03952559
Ruxolitinib (Opzelura)
38.1% vs 9.5%+28.6 vs placebo0.75% Cream BID · wk 8 · n 252NCT03745638
11 other results
  • 44.3% vs 9.5% 1.5% Cream BID · wk 8 · n 253 · Phase 3 · secondary NCT03745638
  • 35.1% vs 4.2% 0.75% cream BID · wk 8 · n 231 · Phase 3 · secondary NCT03745651
  • 43.4% vs 4.2% 1.5% cream BID · wk 8 · n 228 · Phase 3 · secondary NCT03745651
  • 30.6% vs 4% 0.75% Cream BID · wk 4 · n 252 · Phase 3 · secondary NCT03745638
  • 36.4% vs 4% 1.5% Cream BID · wk 4 · n 253 · Phase 3 · secondary NCT03745638
  • 25.5% vs 2.5% 0.75% cream BID · wk 4 · n 231 · Phase 3 · secondary NCT03745651
  • 32.5% vs 2.5% 1.5% cream BID · wk 4 · n 228 · Phase 3 · secondary NCT03745651
  • 12.7% vs 2.4% 0.75% Cream BID · wk 2 · n 252 · Phase 3 · secondary NCT03745638
  • 19.8% vs 2.4% 1.5% Cream BID · wk 2 · n 253 · Phase 3 · secondary NCT03745638
  • 10.8% vs 0.8% 0.75% cream BID · wk 2 · n 231 · Phase 3 · secondary NCT03745651
  • 15.8% vs 0.8% 1.5% cream BID · wk 2 · n 228 · Phase 3 · secondary NCT03745651

EASI, % change

baricitinib
-59.4% vs -34.8%−24.5 vs placebo4 mg · wk 16 · n 70NCT03334396
12 other results
  • -54.9% vs -28.9% 4 mg · wk 16 · n 49 · Phase 3 · secondary NCT03334422
  • -63.3% vs -42.7% 4 mg · wk 16 · n 65 · Phase 3 · secondary NCT03428100
  • -67.2% vs -45.1% 4 mg · wk 16 · n 100 · Phase 3 · secondary NCT03733301
  • -51.9% vs -34.8% 2 mg · wk 16 · n 52 · Phase 3 · secondary NCT03334396
  • -56.0% vs -42.7% 2 mg · wk 16 · n 144 · Phase 3 · secondary NCT03428100
  • -54.8% vs -28.9% 2 mg · wk 16 · n 40 · Phase 3 · secondary NCT03334422
  • -54.4% vs -34.1% 2 mg · wk 16 · n 62 · Phase 3 · secondary NCT03435081
  • -58.2% vs -45.1% 2 mg · wk 16 · n 100 · Phase 3 · secondary NCT03733301
  • -48.2% vs -34.8% 1 mg · wk 16 · n 52 · Phase 3 · secondary NCT03334396
  • -41.7% vs -28.9% 1 mg · wk 16 · n 34 · Phase 3 · secondary NCT03334422
  • -60.3% vs -42.7% 1 mg · wk 16 · n 61 · Phase 3 · secondary NCT03428100
  • -46.7% vs -34.1% 1 mg · wk 16 · n 47 · Phase 3 · secondary NCT03435081
Ruxolitinib (Opzelura)
-71.0% vs -37.9%−33.1 vs placebo0.75% Cream BID · wk 8 · n 252NCT03745638
31 other results
  • -77.4% vs -37.9% 1.5% Cream BID · wk 8 · n 253 · Phase 3 · secondary NCT03745638
  • -73.4% vs -28.8% 0.75% cream BID · wk 8 · n 231 · Phase 3 · secondary NCT03745651
  • -74.8% vs -28.8% 1.5% cream BID · wk 8 · n 228 · Phase 3 · secondary NCT03745651
  • -68.0% vs -23.0% 0.75% Cream BID · wk 4 · n 252 · Phase 3 · secondary NCT03745638
  • -71.1% vs -23.0% 1.5% Cream BID · wk 4 · n 253 · Phase 3 · secondary NCT03745638
  • -65% vs -20.4% 0.75% cream BID · wk 4 · n 231 · Phase 3 · secondary NCT03745651
  • -66.3% vs -20.4% 1.5% cream BID · wk 4 · n 228 · Phase 3 · secondary NCT03745651
  • -51.8% vs -16.3% 0.75% Cream BID · wk 2 · n 252 · Phase 3 · secondary NCT03745638
  • -56.6% vs -16.3% 1.5% Cream BID · wk 2 · n 253 · Phase 3 · secondary NCT03745638
  • -45.9% vs -13.9% 0.75% cream BID · wk 2 · n 231 · Phase 3 · secondary NCT03745651
  • -49.1% vs -13.9% 1.5% cream BID · wk 2 · n 228 · Phase 3 · secondary NCT03745651
  • -71.6% vs -11.9% 1.5% BID · wk 4 · n 49 · Phase 2 · primary NCT03011892
  • -50.2% vs -21.9% 0.15% QD · wk 8 · n 51 · Phase 2 · secondary NCT03011892
  • -58.4% vs -21.9% 0.5% QD · wk 8 · n 51 · Phase 2 · secondary NCT03011892
  • -67.0% vs -21.9% 1.5% QD · wk 8 · n 52 · Phase 2 · secondary NCT03011892
  • -79.0% vs -21.9% 1.5% BID · wk 8 · n 50 · Phase 2 · secondary NCT03011892
  • -44.9% vs -11.9% 0.15% QD · wk 4 · n 47 · Phase 2 · secondary NCT03011892
  • -52.8% vs -11.9% 0.5% QD · wk 4 · n 47 · Phase 2 · secondary NCT03011892
  • -66.7% vs -11.9% 1.5% QD · wk 4 · n 49 · Phase 2 · secondary NCT03011892
  • -45.4% vs -15.5% 0.15% QD · wk 4 · n 47 · Phase 2 · secondary NCT03011892
  • -52.2% vs -15.5% 0.5% QD · wk 4 · n 47 · Phase 2 · secondary NCT03011892
  • -67% vs -15.5% 1.5% QD · wk 4 · n 49 · Phase 2 · secondary NCT03011892
  • -71.6% vs -15.5% 1.5% BID · wk 4 · n 49 · Phase 2 · secondary NCT03011892
  • -30.0% vs -4.8% 0.15% QD · wk 2 · n 51 · Phase 2 · secondary NCT03011892
  • -45.9% vs -4.8% 0.5% QD · wk 2 · n 51 · Phase 2 · secondary NCT03011892
  • -49.9% vs -4.8% 1.5% QD · wk 2 · n 52 · Phase 2 · secondary NCT03011892
  • -52.7% vs -4.8% 1.5% BID · wk 2 · n 50 · Phase 2 · secondary NCT03011892
  • -44.9% vs -59.5% 0.15% QD · wk 4 · n 47 · Phase 2 · secondary NCT03011892
  • -52.8% vs -59.5% 0.5% QD · wk 4 · n 47 · Phase 2 · secondary NCT03011892
  • -66.7% vs -59.5% 1.5% QD · wk 4 · n 49 · Phase 2 · secondary NCT03011892
  • -71.6% vs -59.5% 1.5% BID · wk 4 · n 49 · Phase 2 · secondary NCT03011892
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
11 other shared endpoints and safety

Coverage. baricitinib: 15 of 15 rows · Ruxolitinib (Opzelura): 15 of 15 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricbaricitinib
Rows use multiple source trials
Ruxolitinib (Opzelura)
Rows use multiple source trials
BSA
absolute change · percentage points
-25.66% (n=115) vs -20.31% (n=105) placebo @ 16wkHigh Dosea,b,c,d
NCT03952559 · Phase 3 · registry result, not featured evidence
show 2 more doses
-21.83% (n=109) vs -20.31% (n=105) placebo @ 16wkLow Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-22.06% (n=113) vs -20.31% (n=105) placebo @ 16wkMedium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-6.3% (n=252) vs -2.51% (n=126) placebo @ 8wk0.75% Cream BIDa,b,c,d
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 1 more dose
-6.54% (n=253) vs -2.51% (n=126) placebo @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
CDLQI
absolute change · score
-3.36 vs -3.06 placebo score @ 16wkHigh Dosea,b,c,d
NCT03952559 · Phase 3 · registry result, not featured evidence
show 2 more doses
-3.73 vs -3.06 placebo score @ 16wkLow Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-3.7 vs -3.06 placebo score @ 16wkMedium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-5.88 vs -2.31 placebo score @ 8wk0.75% Cream BIDa,b,c,d
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 1 more dose
-7.61 vs -2.31 placebo score @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
DLQI
absolute change · score
-6.76 vs -2.46 placebo score @ 16wk4 mga,e,d
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 2 more doses
-4.3 vs -2.46 placebo score @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-4.64 vs -2.46 placebo score @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.28 vs -2.83 placebo score @ 8wk0.75% Cream BIDa,e,d
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 1 more dose
-7.72 vs -2.83 placebo score @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
EASI-50
responder rate · % of participants
41.6% (n=125) vs 15.3% (n=249) placebo @ 16wk4 mga,e,d
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 2 more doses
30.1% (n=123) vs 15.3% (n=249) placebo @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
26% (n=127) vs 15.3% (n=249) placebo @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
69.4% (n=252) vs 43.7% (n=126) placebo @ 8wk0.75% Cream BIDa,e,d
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 1 more dose
77.9% (n=253) vs 43.7% (n=126) placebo @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
IGA 0/1
responder rate · % of participants
15.4% (n=123) vs 3.7% (n=244) placebo @ 4wk4 mga,e
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 2 more doses
8.1% (n=123) vs 3.7% (n=244) placebo @ 4wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3.2% (n=125) vs 3.7% (n=244) placebo @ 4wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
53.2% (n=252) vs 15.1% (n=126) placebo @ 4wk0.75% Cream BIDa,e
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 1 more dose
54.9% (n=253) vs 15.1% (n=126) placebo @ 4wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
IGA 0/1
responder rate · % of participants
No placebo or comparator arm
12.3% (n=81) @ 52wk4 mga,b,c
NCT03334435 · Phase 3 · registry result, not featured evidence
show 11 more doses
15.4% (n=78) @ 52wk4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
19% (n=21) @ 52wk4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
20.5% (n=156) @ 52wk4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
5.1% (n=39) @ 52wk4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
23.7% (n=194) @ 52wk4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
10.7% (n=28) @ 52wk4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
12.6% (n=87) @ 52wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
19% (n=84) @ 52wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
15% (n=20) @ 52wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
20.6% (n=180) @ 52wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
5.9% (n=34) @ 52wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
76.9% (n=222) @ 52wk0.75% Creama,b,c
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 1 more dose
75.4% (n=225) @ 52wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Itch NRS
absolute change · score
-33.16 vs -15.35 placebo score @ 24wk4 mga,b,c,f
NCT03428100 · Phase 3 · registry result, not featured evidence
show 2 more doses
-30.11 vs -15.35 placebo score @ 24wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-29.35 vs -15.35 placebo score @ 24wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-3.14 vs -1.54 placebo score @ 8wk0.75% Cream BIDa,b,c,f
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 1 more dose
-3.53 vs -1.54 placebo score @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Itch NRS ≥4
responder rate · % of participants
35.5% (n=62) vs 16.4% (n=55) placebo @ 16wkHigh Dosea,b,c,d
NCT03952559 · Phase 3 · registry result, not featured evidence
show 2 more doses
17.5% (n=63) vs 16.4% (n=55) placebo @ 16wkLow Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
25.8% (n=62) vs 16.4% (n=55) placebo @ 16wkMedium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
42.7% (n=157) vs 16.3% (n=80) placebo @ 8wk0.75% cream BIDa,b,c,d
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 1 more dose
50.7% (n=146) vs 16.3% (n=80) placebo @ 8wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Itch NRS 4-Point Improvement
responder rate · % of participants
21.5% (n=107) vs 7.2% (n=222) placebo @ 16wk4 mga,e,d
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 2 more doses
12% (n=100) vs 7.2% (n=222) placebo @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
10.5% (n=105) vs 7.2% (n=222) placebo @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
40.4% (n=156) vs 15.4% (n=78) placebo @ 8wk0.75% Cream BIDa,e,d
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 1 more dose
52.2% (n=161) vs 15.4% (n=78) placebo @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
POEM
absolute change · score
-7.56 vs -1.48 placebo score @ 16wk4 mga,e,d
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 2 more doses
-7.06 vs -1.48 placebo score @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.85 vs -1.48 placebo score @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-10.6 vs -4.3 placebo score @ 8wk0.75% Cream BIDa,e,d
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 1 more dose
-11.82 vs -4.3 placebo score @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Skin Pain NRS
absolute change · score
-1.93 vs -0.84 placebo score @ 16wk4 mga,e,d
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 2 more doses
-1.58 vs -0.84 placebo score @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.92 vs -0.84 placebo score @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.55 vs -1.16 placebo score @ 8wk0.75% Cream BIDa,e,d
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 1 more dose
-2.84 vs -1.16 placebo score @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Dropout rate
4%4 mgg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 50 more results
—4 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
8.1%2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
8.7%1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
4.9%4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
8.1%2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
8%1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—High Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—Low Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—Medium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—Mid Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—High Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
98%4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
97.7%2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
7.6%4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—Placebo to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—4 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—4 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
6.5%2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—Placebo to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
14%1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—1 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—1 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
13%2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
3.6%4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
8.3%2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
—4 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
32.4%2 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
—0.75% Creamh
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 32 more results
—1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
11.9%0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
11.1%1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
15.7%0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
8.9%1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
10.7%1.5% Cream BID
NCT05456529 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% Cream BID
NCT04921969 · Phase 3
—1.5% Cream BID
NCT04921969 · Phase 3
—0.75% Cream BID
NCT04921969 · Phase 3
—1.5% Cream BID
NCT04921969 · Phase 3
10.4%0.75% Cream BID
NCT04921969 · Phase 3
12.2%1.5% Cream BID
NCT04921969 · Phase 3
3.1%1.5%
NCT06238817 · Phase 3 · registry result, not featured evidence
11.1%1.5% BID
NCT05127421 · Phase 2 · registry result, not featured evidence
—1.5% BID
NCT05127421 · Phase 2 · registry result, not featured evidence
—1.5% BID
NCT05127421 · Phase 2 · registry result, not featured evidence
10.2%1.5% Cream BID
NCT04839380 · Phase 2 · registry result, not featured evidence
13.7%0.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
10%1.5% BID
NCT03011892 · Phase 2 · registry result, not featured evidence
13.5%1.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
—0.15% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
—0.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
—1.5% BID
NCT03011892 · Phase 2 · registry result, not featured evidence
—1.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0%4 mgg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 50 more results
—4 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.8%2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.6%4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.6%2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.4%1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—High Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—Low Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—Medium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—Mid Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—High Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
3.1%4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
1.7%2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
1.1%4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—Placebo to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—4 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—4 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
1.6%2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—Placebo to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
0%1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—1 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—1 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
1.4%2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
2.7%4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
0.9%2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
—4 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
8.1%2 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
—0.75% Creamh
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 32 more results
—1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.8%0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.4%1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.4%0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% Cream BID
NCT05456529 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% Cream BID
NCT04921969 · Phase 3
—1.5% Cream BID
NCT04921969 · Phase 3
—0.75% Cream BID
NCT04921969 · Phase 3
—1.5% Cream BID
NCT04921969 · Phase 3
0.7%0.75% Cream BID
NCT04921969 · Phase 3
0.8%1.5% Cream BID
NCT04921969 · Phase 3
0%1.5%
NCT06238817 · Phase 3 · registry result, not featured evidence
—1.5% BID
NCT05127421 · Phase 2 · registry result, not featured evidence
—1.5% BID
NCT05127421 · Phase 2 · registry result, not featured evidence
—1.5% BID
NCT05127421 · Phase 2 · registry result, not featured evidence
—1.5% Cream BID
NCT04839380 · Phase 2 · registry result, not featured evidence
0%0.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
0%1.5% BID
NCT03011892 · Phase 2 · registry result, not featured evidence
0%1.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
—0.15% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
—0.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
—1.5% BID
NCT03011892 · Phase 2 · registry result, not featured evidence
—1.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
Serious AEs
1.6%4 mgg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 50 more results
0%4 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.8%1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.8%4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.4%2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
7.3%1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.8%High Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
1.7%Low Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—Medium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
0.8%Mid Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
0%High Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
9.5%4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
13.1%4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
5.4%4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
6.4%2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
3.3%2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
1.2%2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
4.2%2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
9.4%1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
1.1%1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
2.2%1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
10.9%4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
16.7%4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
28.6%4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
16.7%Placebo to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
18.8%4 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
18.8%4 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
4.9%2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
4.5%2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
11.1%2 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
19.2%2 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
9.1%Placebo to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
16%2 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
12.5%2 mg to 1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
7.5%1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
2.9%1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
15.4%1 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
21.4%1 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
1.4%2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
0%2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
0.7%1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
0%1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
3.6%4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
1.8%2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
2.6%4 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
5.4%2 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
—0.75% Creamh
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 32 more results
—1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3%0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2%1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.7%0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.3%1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.9%1.5% Cream BID
NCT05456529 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—0.75% Cream BID
NCT04921969 · Phase 3
—1.5% Cream BID
NCT04921969 · Phase 3
0%0.75% Cream BID
NCT04921969 · Phase 3
1.9%1.5% Cream BID
NCT04921969 · Phase 3
—0.75% Cream BID
NCT04921969 · Phase 3
—1.5% Cream BID
NCT04921969 · Phase 3
2%1.5%
NCT06238817 · Phase 3 · registry result, not featured evidence
—1.5% BID
NCT05127421 · Phase 2 · registry result, not featured evidence
—1.5% BID
NCT05127421 · Phase 2 · registry result, not featured evidence
0%1.5% BID
NCT05127421 · Phase 2 · registry result, not featured evidence
0%1.5% Cream BID
NCT04839380 · Phase 2 · registry result, not featured evidence
—0.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
—1.5% BID
NCT03011892 · Phase 2 · registry result, not featured evidence
—1.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
0%0.15% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
0%0.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
0%1.5% BID
NCT03011892 · Phase 2 · registry result, not featured evidence
0%1.5% QD
NCT03011892 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
4 mgg
nasopharyngitis 9.6% (placebo 10.4%)
headache 8% (placebo 6.4%)
cough 3.2% (placebo 0.8%)
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 47 more results
4 mg
abdominal pain 12.5% (placebo 0.4%)
nausea 12.5% (placebo 0.8%)
oedema peripheral 12.5% (placebo 0.4%)
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2 mg
headache 11.4% (placebo 6.4%)
nasopharyngitis 9.8% (placebo 10.4%)
abdominal pain 2.4% (placebo 0.4%)
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2 mg
pyrexia 12.5% (placebo 0%)
urinary tract infection 12.5% (placebo 1.6%)
abdominal pain 0% (placebo 0.4%)
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1 mg
nasopharyngitis 17.3% (placebo 10.4%)
diarrhoea 7.1% (placebo 2.8%)
headache 5.5% (placebo 6.4%)
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1 mg
pyrexia 20% (placebo 0%)
abdominal pain 0% (placebo 0.4%)
anaemia 0% (placebo 0.4%)
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
4 mg
headache 8.9% (placebo 2%)
nasopharyngitis 8.1% (placebo 12.3%)
blood creatine phosphokinase increased 5.7% (placebo 0.4%)
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2 mg
nasopharyngitis 13% (placebo 12.3%)
headache 7.3% (placebo 2%)
herpes simplex 5.7% (placebo 0.8%)
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1 mg
nasopharyngitis 10.5% (placebo 12.3%)
headache 4.8% (placebo 2%)
blood creatine phosphokinase increased 3.2% (placebo 0.4%)
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
High Dose
abdominal pain 5% (placebo 2.5%)
acne 5% (placebo 4.1%)
headache 5% (placebo 8.2%)
NCT03952559 · Phase 3 · registry result, not featured evidence
Low Dose
headache 5.8% (placebo 8.2%)
bronchitis 5% (placebo 0.8%)
covid-19 4.2% (placebo 2.5%)
NCT03952559 · Phase 3 · registry result, not featured evidence
Mid Dose
headache 9.2% (placebo 8.2%)
abdominal pain 4.2% (placebo 2.5%)
covid-19 4.2% (placebo 2.5%)
NCT03952559 · Phase 3 · registry result, not featured evidence
High Dose
nasopharyngitis 6.1% (placebo 4.9%)
abdominal pain upper 3% (placebo 0.8%)
chapped lips 3% (placebo 0%)
NCT03952559 · Phase 3 · registry result, not featured evidence
4 mg
covid-19 11% (placebo 2.2%)
herpes zoster 9.8% (placebo 0%)
nasopharyngitis 9.8% (placebo 5.4%)
NCT03334435 · Phase 3 · registry result, not featured evidence
4 mg
covid-19 16.7% (placebo 2.2%)
nasopharyngitis 13.1% (placebo 5.4%)
blood creatine phosphokinase increased 6% (placebo 1.1%)
NCT03334435 · Phase 3 · registry result, not featured evidence
4 mg
nasopharyngitis 16.4% (placebo 5.4%)
upper respiratory tract infection 5.9% (placebo 4.3%)
oral herpes 5.4% (placebo 1.1%)
NCT03334435 · Phase 3 · registry result, not featured evidence
2 mg
covid-19 13.3% (placebo 2.2%)
nasopharyngitis 10.8% (placebo 5.4%)
headache 5.6% (placebo 3.3%)
NCT03334435 · Phase 3 · registry result, not featured evidence
2 mg
covid-19 15.2% (placebo 2.2%)
nasopharyngitis 10.9% (placebo 5.4%)
headache 5.4% (placebo 3.3%)
NCT03334435 · Phase 3 · registry result, not featured evidence
2 mg
nasopharyngitis 9.5% (placebo 5.4%)
urinary tract infection 7.1% (placebo 1.1%)
covid-19 4.8% (placebo 2.2%)
NCT03334435 · Phase 3 · registry result, not featured evidence
2 mg
nasopharyngitis 13.8% (placebo 5.4%)
headache 6% (placebo 3.3%)
upper respiratory tract infection 5.6% (placebo 4.3%)
NCT03334435 · Phase 3 · registry result, not featured evidence
1 mg
covid-19 21.9% (placebo 2.2%)
alanine aminotransferase increased 9.4% (placebo 0%)
dermal cyst 6.3% (placebo 0%)
NCT03334435 · Phase 3 · registry result, not featured evidence
1 mg
covid-19 9.9% (placebo 2.2%)
vulvovaginal candidiasis 6.7% (placebo 0%)
folliculitis 5.5% (placebo 0%)
NCT03334435 · Phase 3 · registry result, not featured evidence
1 mg
nasopharyngitis 20% (placebo 5.4%)
pyrexia 4.4% (placebo 0%)
blood creatine phosphokinase increased 2.2% (placebo 1.1%)
NCT03334435 · Phase 3 · registry result, not featured evidence
4 mg
nasopharyngitis 37% (placebo 10.3%)
influenza 15.2% (placebo 3.4%)
headache 10.9% (placebo 3.4%)
NCT03428100 · Phase 3 · registry result, not featured evidence
4 mg
covid-19 16.7% (placebo 13.8%)
dysmenorrhoea 14.3% (placebo 0%)
upper respiratory tract infection 12.5% (placebo 3.4%)
NCT03428100 · Phase 3 · registry result, not featured evidence
4 mg
nasopharyngitis 57.1% (placebo 10.3%)
covid-19 28.6% (placebo 13.8%)
gastroenteritis 28.6% (placebo 0%)
NCT03428100 · Phase 3 · registry result, not featured evidence
Placebo to 4 mg
nasopharyngitis 50% (placebo 10.3%)
abdominal pain upper 16.7% (placebo 0%)
migraine 16.7% (placebo 0%)
NCT03428100 · Phase 3 · registry result, not featured evidence
4 mg to 2 mg
nasopharyngitis 18.8% (placebo 10.3%)
upper respiratory tract infection 18.8% (placebo 3.4%)
arthralgia 12.5% (placebo 3.4%)
NCT03428100 · Phase 3 · registry result, not featured evidence
4 mg to 4 mg
covid-19 25% (placebo 13.8%)
bronchitis 18.8% (placebo 0%)
herpes simplex 18.8% (placebo 6.9%)
NCT03428100 · Phase 3 · registry result, not featured evidence
2 mg
nasopharyngitis 19.6% (placebo 10.3%)
influenza 8.2% (placebo 3.4%)
headache 7.6% (placebo 3.4%)
NCT03428100 · Phase 3 · registry result, not featured evidence
2 mg
nasopharyngitis 22.7% (placebo 10.3%)
covid-19 18.2% (placebo 13.8%)
herpes zoster 13.6% (placebo 0%)
NCT03428100 · Phase 3 · registry result, not featured evidence
2 mg to 2 mg
covid-19 14.8% (placebo 13.8%)
vulvovaginal candidiasis 14.3% (placebo 0%)
nasopharyngitis 11.1% (placebo 10.3%)
NCT03428100 · Phase 3 · registry result, not featured evidence
2 mg to 4 mg
covid-19 19.2% (placebo 13.8%)
herpes zoster 15.4% (placebo 0%)
skin infection 15.4% (placebo 3.4%)
NCT03428100 · Phase 3 · registry result, not featured evidence
Placebo to 2 mg
acne 9.1% (placebo 0%)
anaemia 9.1% (placebo 0%)
covid-19 9.1% (placebo 13.8%)
NCT03428100 · Phase 3 · registry result, not featured evidence
2 mg to 2 mg
headache 20% (placebo 3.4%)
vulvovaginal candidiasis 20% (placebo 0%)
covid-19 16% (placebo 13.8%)
NCT03428100 · Phase 3 · registry result, not featured evidence
2 mg to 1 mg
nasopharyngitis 33.3% (placebo 10.3%)
covid-19 12.5% (placebo 13.8%)
pain in extremity 12.5% (placebo 3.4%)
NCT03428100 · Phase 3 · registry result, not featured evidence
1 mg
nasopharyngitis 17.2% (placebo 10.3%)
folliculitis 9.7% (placebo 0%)
headache 8.6% (placebo 3.4%)
NCT03428100 · Phase 3 · registry result, not featured evidence
1 mg
dysmenorrhoea 23.1% (placebo 0%)
covid-19 17.6% (placebo 13.8%)
nasopharyngitis 11.8% (placebo 10.3%)
NCT03428100 · Phase 3 · registry result, not featured evidence
1 mg to 2 mg
herpes simplex 15.4% (placebo 6.9%)
herpes zoster 15.4% (placebo 0%)
nasopharyngitis 15.4% (placebo 10.3%)
NCT03428100 · Phase 3 · registry result, not featured evidence
1 mg to 4 mg
conjunctivitis 21.4% (placebo 0%)
covid-19 21.4% (placebo 13.8%)
uterine polypectomy 16.7% (placebo 0%)
NCT03428100 · Phase 3 · registry result, not featured evidence
2 mg
upper respiratory tract infection 6.9% (placebo 6.2%)
nasopharyngitis 6.2% (placebo 7.5%)
diarrhoea 4.1% (placebo 1.4%)
NCT03435081 · Phase 3 · registry result, not featured evidence
2 mg
prostate cancer 9.1% (placebo 0%)
upper respiratory tract infection 8.6% (placebo 6.2%)
urinary tract infection 8.6% (placebo 2.1%)
NCT03435081 · Phase 3 · registry result, not featured evidence
1 mg
upper respiratory tract infection 6.1% (placebo 6.2%)
back pain 2% (placebo 0.7%)
blood creatine phosphokinase increased 2% (placebo 0.7%)
NCT03435081 · Phase 3 · registry result, not featured evidence
1 mg
upper respiratory tract infection 10.5% (placebo 6.2%)
ovarian cyst ruptured 6.7% (placebo 0%)
actinic keratosis 5.3% (placebo 0%)
NCT03435081 · Phase 3 · registry result, not featured evidence
4 mg
nasopharyngitis 15.3% (placebo 12%)
folliculitis 5.4% (placebo 0%)
upper respiratory tract infection 2.7% (placebo 1.9%)
NCT03733301 · Phase 3 · registry result, not featured evidence
2 mg
nasopharyngitis 11% (placebo 12%)
upper respiratory tract infection 7.3% (placebo 1.9%)
folliculitis 3.7% (placebo 0%)
NCT03733301 · Phase 3 · registry result, not featured evidence
4 mg
blood creatine phosphokinase increased 13.2% (placebo 2%)
headache 13.2% (placebo 0%)
nasopharyngitis 10.5% (placebo 4.1%)
NCT02576938 · Phase 2 · registry result, not featured evidence
2 mg
dermatitis atopic 8.1% (placebo 10.2%)
gastrooesophageal reflux disease 5.4% (placebo 0%)
headache 5.4% (placebo 0%)
NCT02576938 · Phase 2 · registry result, not featured evidence
0.75% Cream BIDh
upper respiratory tract infection 9% (placebo 3.2%)
nasopharyngitis 6% (placebo 1.6%)
headache 3.7% (placebo 4%)
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 13 more results
1.5% Cream BID
upper respiratory tract infection 12% (placebo 3.2%)
nasopharyngitis 10.3% (placebo 1.6%)
headache 5.3% (placebo 4%)
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.75% cream BID
nasopharyngitis 9.3% (placebo 0%)
upper respiratory tract infection 7.6% (placebo 0.8%)
application site pain 0.7% (placebo 6.5%)
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.5% cream BID
nasopharyngitis 9.1% (placebo 0%)
upper respiratory tract infection 7.7% (placebo 0.8%)
application site pain 0.7% (placebo 6.5%)
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.5% Cream BID
upper respiratory tract infection 10.7%
nasopharyngitis 8.7%
NCT05456529 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.75% Cream BID
upper respiratory tract infection 13.8% (placebo 3.1%)
covid-19 8.2% (placebo 1.5%)
pyrexia 6.3% (placebo 0%)
NCT04921969 · Phase 3
1.5% Cream BID
upper respiratory tract infection 14.9% (placebo 3.1%)
nasopharyngitis 13% (placebo 1.5%)
covid-19 7.1% (placebo 1.5%)
NCT04921969 · Phase 3
1.5%
upper respiratory tract infection 10.3% (placebo 4.9%)
nasopharyngitis 5.9% (placebo 4.9%)
application site pain 1% (placebo 6.2%)
NCT06238817 · Phase 3 · registry result, not featured evidence
1.5% BID
application site reaction 1.4% (placebo 8.7%)
NCT05127421 · Phase 2 · registry result, not featured evidence
1.5% Cream BID
covid-19 6.1%
back pain 4.1%
headache 4.1%
NCT04839380 · Phase 2 · registry result, not featured evidence
0.15% QD
nasopharyngitis 5.9% (placebo 7.7%)
upper respiratory tract infection 3.9% (placebo 5.8%)
dermatitis atopic 2% (placebo 7.7%)
NCT03011892 · Phase 2 · registry result, not featured evidence
0.5% QD
nasopharyngitis 2% (placebo 7.7%)
upper respiratory tract infection 2% (placebo 5.8%)
dermatitis atopic 0% (placebo 7.7%)
NCT03011892 · Phase 2 · registry result, not featured evidence
1.5% BID
nasopharyngitis 5% (placebo 7.7%)
upper respiratory tract infection 2.7% (placebo 5.8%)
dermatitis atopic 1.5% (placebo 7.7%)
NCT03011892 · Phase 2 · registry result, not featured evidence
1.5% QD
nasopharyngitis 7.8% (placebo 7.7%)
dermatitis atopic 3.9% (placebo 7.7%)
upper respiratory tract infection 2% (placebo 5.8%)
NCT03011892 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 16 weeks versus 8 weeks.
  5. ePopulation context differs: baseline_threshold differs (none recorded versus bsa>=3); prior_therapy differs (experienced versus none recorded).
  6. fAssessment timepoints differ: 24 weeks versus 8 weeks.
  7. gPopulation comparability has not been reviewed for 42 of these studies.
  8. hPopulation comparability has not been reviewed for 18 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

baricitinib

IGA 0 1 Improvement 16.8% (n=125) vs 4.8% (n=249) placebo @ 16wk4 mg
responder rate · % of participants
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 5 more results
10.4% (n=125) vs 2.4% (n=249) placebo @ 4wk4 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
11.4% (n=123) vs 4.8% (n=249) placebo @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
8.9% (n=123) vs 2.4% (n=249) placebo @ 4wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
11.8% (n=127) vs 4.8% (n=249) placebo @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3.1% (n=127) vs 2.4% (n=249) placebo @ 4wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
SCORAD75 10.4% (n=125) vs 1.2% (n=249) placebo @ 16wk4 mg
responder rate · % of participants
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 15 more results
11.4% (n=123) vs 1.6% (n=244) placebo @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
6.5% (n=92) vs 1.1% (n=93) placebo @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
18% (n=111) vs 7.3% (n=109) placebo @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
7.3% (n=123) vs 1.2% (n=249) placebo @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
7.3% (n=123) vs 1.6% (n=244) placebo @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
8.1% (n=185) vs 1.1% (n=93) placebo @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
14.4% (n=146) vs 2.7% (n=147) placebo @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
11% (n=109) vs 7.3% (n=109) placebo @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
5.5% (n=127) vs 1.2% (n=249) placebo @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
4.8% (n=125) vs 1.6% (n=244) placebo @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
6.5% (n=93) vs 1.1% (n=93) placebo @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
3.4% (n=147) vs 2.7% (n=147) placebo @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
7.4% (n=121) vs 9.8% (n=122) placebo @ 16wkLow Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
15.8% (n=120) vs 9.8% (n=122) placebo @ 16wkMedium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
20% (n=120) vs 9.8% (n=122) placebo @ 16wkHigh Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
ADSS Item 2 -1.42 vs -0.84 placebo score @ 16wk4 mg
absolute change · score
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 15 more results
-1.38 vs -0.8 placebo score @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.42 vs -0.63 placebo score @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-1.42 vs -0.51 placebo score @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-1.04 vs -0.84 placebo score @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.21 vs -0.8 placebo score @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.85 vs -0.63 placebo score @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-0.99 vs -0.4 placebo score @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
-1.33 vs -0.51 placebo score @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-1.21 vs -0.84 placebo score @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.1 vs -0.8 placebo score @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.05 vs -0.63 placebo score @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-0.62 vs -0.4 placebo score @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
-0.35 vs -0.42 placebo score @ 16wkLow Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-0.43 vs -0.42 placebo score @ 16wkMedium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-0.55 vs -0.42 placebo score @ 16wkHigh Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
IGA 0 1.6% (n=125) vs 0.8% (n=249) placebo @ 16wk4 mg
responder rate · % of participants
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 15 more results
4.1% (n=123) vs 1.6% (n=244) placebo @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3.3% (n=92) vs 0% (n=93) placebo @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
8.1% (n=111) vs 2.8% (n=109) placebo @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
2.4% (n=123) vs 0.8% (n=249) placebo @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
4.1% (n=123) vs 1.6% (n=244) placebo @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.1% (n=185) vs 0% (n=93) placebo @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
2.7% (n=146) vs 0.7% (n=147) placebo @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
3.7% (n=109) vs 2.8% (n=109) placebo @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
1.6% (n=127) vs 0.8% (n=249) placebo @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.4% (n=125) vs 1.6% (n=244) placebo @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.2% (n=93) vs 0% (n=93) placebo @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
3.4% (n=147) vs 0.7% (n=147) placebo @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
5% (n=121) vs 4.1% (n=122) placebo @ 16wkLow Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
5% (n=120) vs 4.1% (n=122) placebo @ 16wkMedium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
12.5% (n=120) vs 4.1% (n=122) placebo @ 16wkHigh Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
SCORAD -28.3 vs -13.51 placebo score @ 16wk4 mg
absolute change · score
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 17 more results
-27.5 vs -13.35 placebo score @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-31.74 vs -21.98 placebo score @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-35.78 vs -21.4 placebo score @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-26.54 vs -11.89 placebo score @ 16wk4 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
-21.47 vs -13.51 placebo score @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-27.83 vs -13.35 placebo score @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-28.54 vs -21.98 placebo score @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-26.18 vs -14.37 placebo score @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
-29.88 vs -21.4 placebo score @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-23.87 vs -11.89 placebo score @ 16wk2 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
-18.85 vs -13.51 placebo score @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-20.23 vs -13.35 placebo score @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-28.06 vs -21.98 placebo score @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-18.31 vs -14.37 placebo score @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
-24.82 vs -20.93 placebo score @ 16wkLow Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-26.08 vs -20.93 placebo score @ 16wkMedium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-28.55 vs -20.93 placebo score @ 16wkHigh Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
SCORAD90 2.4% (n=125) vs 0.8% (n=249) placebo @ 16wk4 mg
responder rate · % of participants
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 15 more results
4.9% (n=123) vs 1.2% (n=244) placebo @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.2% (n=92) vs 0% (n=93) placebo @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
7.2% (n=111) vs 0.9% (n=109) placebo @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
2.4% (n=123) vs 0.8% (n=249) placebo @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
4.1% (n=123) vs 1.2% (n=244) placebo @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.1% (n=185) vs 0% (n=93) placebo @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
3.4% (n=146) vs 1.4% (n=147) placebo @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
3.7% (n=109) vs 0.9% (n=109) placebo @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
0.8% (n=127) vs 0.8% (n=249) placebo @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3.2% (n=125) vs 1.2% (n=244) placebo @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.2% (n=93) vs 0% (n=93) placebo @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
2% (n=147) vs 1.4% (n=147) placebo @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
1.7% (n=121) vs 3.3% (n=122) placebo @ 16wkLow Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
5% (n=120) vs 3.3% (n=122) placebo @ 16wkMedium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
12.5% (n=120) vs 3.3% (n=122) placebo @ 16wkHigh Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
BSA -25.96 vs -14.8 placebo score @ 16wk4 mg
absolute change · score
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 10 more results
-23.98 vs 12.82 placebo score @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-28.17 vs -19.76 placebo score @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-29.73 vs -18.03 placebo score @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-20.14 vs -14.8 placebo score @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-22.12 vs 12.82 placebo score @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-25.26 vs -19.76 placebo score @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-27 vs -18.03 placebo score @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-20.79 vs -14.8 placebo score @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-18.98 vs 12.82 placebo score @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-25.98 vs -19.76 placebo score @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
Itch NRS -36.55% (n=68) vs -12.04% (n=68) placebo @ 16wk4 mg
percent change · % of baseline
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 15 more results
46.87% (n=47) vs -16.58% (n=48) placebo @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-37.24% (n=66) vs -17.48% (n=53) placebo @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-29.31% (n=56) vs -12.13% (n=44) placebo @ 52wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-51.22% (n=94) vs -27% (n=89) placebo @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-29.43% (n=50) vs -12.04% (n=68) placebo @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
47.24% (n=38) vs -16.58% (n=48) placebo @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-32.89% (n=135) vs -17.48% (n=53) placebo @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-16.01% (n=110) vs -12.13% (n=44) placebo @ 52wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-39.87% (n=73) vs -18.01% (n=36) placebo @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
-43.44% (n=98) vs -27% (n=89) placebo @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-31.3% (n=52) vs -12.04% (n=68) placebo @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-31.39% (n=31) vs -16.58% (n=48) placebo @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-28.8% (n=62) vs -17.48% (n=53) placebo @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-19.49% (n=54) vs -12.13% (n=44) placebo @ 52wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-30.28% (n=64) vs -18.01% (n=36) placebo @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
POEM Total -7.84 vs -2.68 placebo score @ 16wk4 mg
absolute change · score
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 6 more results
-10.83 vs -5.6 placebo score @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-6.26 vs -2.68 placebo score @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.44 vs -2.67 placebo score @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
-8.5 vs -5.6 placebo score @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-5.32 vs -2.68 placebo score @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-4.57 vs -2.67 placebo score @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
PGI-S-AD -0.77 vs -0.31 placebo score @ 16wk4 mg
absolute change · score
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 10 more results
-0.96 vs -0.27 placebo score @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.18 vs -0.69 placebo score @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-0.58 vs -0.31 placebo score @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.88 vs -0.27 placebo score @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.06 vs -0.69 placebo score @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-0.58 vs -0.31 placebo score @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.53 vs -0.27 placebo score @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.56 vs -0.33 placebo score @ 16wkLow Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-0.64 vs -0.33 placebo score @ 16wkMedium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-0.83 vs -0.33 placebo score @ 16wkHigh Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
HADS Anxiety -2.05 vs -0.9 placebo score @ 16wk4 mg
absolute change · score
Anxiety
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 12 more results
-2.3 vs -0.99 placebo score @ 16wk4 mg
Anxiety
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.32 vs -0.48 placebo score @ 16wk4 mg
Anxiety
NCT03428100 · Phase 3 · registry result, not featured evidence
-2.8 vs -1.89 placebo score @ 16wk4 mg
Anxiety
NCT03733301 · Phase 3 · registry result, not featured evidence
-1.83 vs -0.9 placebo score @ 16wk2 mg
Anxiety
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.92 vs -0.99 placebo score @ 16wk2 mg
Anxiety
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.59 vs -0.48 placebo score @ 16wk2 mg
Anxiety
NCT03428100 · Phase 3 · registry result, not featured evidence
-2.55 vs -2.03 placebo score @ 16wk2 mg
Anxiety
NCT03435081 · Phase 3 · registry result, not featured evidence
-2.7 vs -1.89 placebo score @ 16wk2 mg
Anxiety
NCT03733301 · Phase 3 · registry result, not featured evidence
-1.35 vs -0.9 placebo score @ 16wk1 mg
Anxiety
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.93 vs -0.99 placebo score @ 16wk1 mg
Anxiety
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.04 vs -0.48 placebo score @ 16wk1 mg
Anxiety
NCT03428100 · Phase 3 · registry result, not featured evidence
-1.5 vs -2.03 placebo score @ 16wk1 mg
Anxiety
NCT03435081 · Phase 3 · registry result, not featured evidence
HADS Depression -1.5 vs -0.37 placebo score @ 16wk4 mg
absolute change · score
Depression
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 12 more results
-1.46 vs -0.28 placebo score @ 16wk4 mg
Depression
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.57 vs -0.4 placebo score @ 16wk4 mg
Depression
NCT03428100 · Phase 3 · registry result, not featured evidence
-2.33 vs -1.31 placebo score @ 16wk4 mg
Depression
NCT03733301 · Phase 3 · registry result, not featured evidence
-1.4 vs -0.37 placebo score @ 16wk2 mg
Depression
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.99 vs -0.28 placebo score @ 16wk2 mg
Depression
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.03 vs -0.4 placebo score @ 16wk2 mg
Depression
NCT03428100 · Phase 3 · registry result, not featured evidence
-1.73 vs -1.31 placebo score @ 16wk2 mg
Depression
NCT03435081 · Phase 3 · registry result, not featured evidence
-2.05 vs -1.31 placebo score @ 16wk2 mg
Depression
NCT03733301 · Phase 3 · registry result, not featured evidence
-1.04 vs -0.37 placebo score @ 16wk1 mg
Depression
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.78 vs -0.28 placebo score @ 16wk1 mg
Depression
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.69 vs -0.4 placebo score @ 16wk1 mg
Depression
NCT03428100 · Phase 3 · registry result, not featured evidence
-0.87 vs -1.31 placebo score @ 16wk1 mg
Depression
NCT03435081 · Phase 3 · registry result, not featured evidence

+ 25 further endpoints in the CSV export.

Ruxolitinib (Opzelura)

IGA-TS 50% (n=252) vs 15.1% (n=126) placebo @ 8wk0.75% Cream BID
responder rate · % of participants
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 17 more results
53.8% (n=253) vs 15.1% (n=126) placebo @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
22.2% (n=252) vs 3.2% (n=126) placebo @ 2wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
27.3% (n=253) vs 3.2% (n=126) placebo @ 2wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
42.5% (n=252) vs 6.3% (n=126) placebo @ 4wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
46.6% (n=253) vs 6.3% (n=126) placebo @ 4wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
39% (n=231) vs 7.6% (n=118) placebo @ 8wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
51.3% (n=228) vs 7.6% (n=118) placebo @ 8wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
17.3% (n=231) vs 4.2% (n=118) placebo @ 2wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
25% (n=228) vs 4.2% (n=118) placebo @ 2wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
35.5% (n=231) vs 5.9% (n=118) placebo @ 4wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
43.4% (n=228) vs 5.9% (n=118) placebo @ 4wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
36.6% (n=134) vs 10.8% (n=65) placebo @ 8wk0.75% Cream BID
NCT04921969 · Phase 3
56.5% (n=131) vs 10.8% (n=65) placebo @ 8wk1.5% Cream BID
NCT04921969 · Phase 3
24.6% (n=134) vs 4.6% (n=65) placebo @ 2wk0.75% Cream BID
NCT04921969 · Phase 3
35.1% (n=131) vs 4.6% (n=65) placebo @ 2wk1.5% Cream BID
NCT04921969 · Phase 3
36.6% (n=134) vs 12.3% (n=65) placebo @ 4wk0.75% Cream BID
NCT04921969 · Phase 3
48.1% (n=131) vs 12.3% (n=65) placebo @ 4wk1.5% Cream BID
NCT04921969 · Phase 3
Sleep Disturbance 6-Point Improvement 21% (n=233) vs 9.5% (n=116) placebo @ 8wk0.75% Cream BID
responder rate · % of participants
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 5 more results
22.3% (n=238) vs 9.5% (n=116) placebo @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
13.7% (n=233) vs 5.2% (n=116) placebo @ 2wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
14.7% (n=238) vs 5.2% (n=116) placebo @ 2wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
19.3% (n=233) vs 6.9% (n=116) placebo @ 4wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
21% (n=238) vs 6.9% (n=116) placebo @ 4wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
Sleep-Related Impairment 6-Point Improvement 20.2% (n=233) vs 13.2% (n=114) placebo @ 8wk0.75% Cream BID
responder rate · % of participants
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 5 more results
21.6% (n=245) vs 13.2% (n=114) placebo @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
16.3% (n=233) vs 8.8% (n=114) placebo @ 2wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
13.5% (n=245) vs 8.8% (n=114) placebo @ 2wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
20.6% (n=233) vs 13.2% (n=114) placebo @ 4wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
19.2% (n=245) vs 13.2% (n=114) placebo @ 4wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
SCORAD -43.96% (n=252) vs -16.67% (n=126) placebo @ 2wk0.75% Cream BID
percent change · % of baseline
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 11 more results
-49.32% (n=253) vs -16.67% (n=126) placebo @ 2wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-57.8% (n=252) vs -27.68% (n=126) placebo @ 4wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-61.33% (n=253) vs -27.68% (n=126) placebo @ 4wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-62.14% (n=252) vs -37% (n=126) placebo @ 8wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-67.24% (n=253) vs -37% (n=126) placebo @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-39.62% (n=231) vs -13.87% (n=118) placebo @ 2wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-45.22% (n=228) vs -13.87% (n=118) placebo @ 2wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-54.85% (n=231) vs -21.79% (n=118) placebo @ 4wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-58.76% (n=228) vs -21.79% (n=118) placebo @ 4wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-63.71% (n=231) vs -23.63% (n=118) placebo @ 8wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-67.39% (n=228) vs -23.63% (n=118) placebo @ 8wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
PROMIS Sleep Disturbance -1.72 vs -0.18 placebo score @ 2wk0.75% Cream BID
absolute change · score
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 11 more results
-2.49 vs -0.18 placebo score @ 2wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.58 vs -0.25 placebo score @ 4wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.1 vs -0.25 placebo score @ 4wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.97 vs -0.43 placebo score @ 8wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.62 vs -0.43 placebo score @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.92 vs -1.32 placebo score @ 2wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.3 vs -1.32 placebo score @ 2wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.32 vs -2.02 placebo score @ 4wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.88 vs -2.02 placebo score @ 4wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.3 vs -2.6 placebo score @ 8wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.4 vs -2.6 placebo score @ 8wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
PROMIS Sleep-Related Impairment -1.76 vs -0.58 placebo score @ 2wk0.75% Cream BID
absolute change · score
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 11 more results
-2.25 vs -0.58 placebo score @ 2wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.71 vs -1.06 placebo score @ 4wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.97 vs -1.06 placebo score @ 4wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.34 vs -1.22 placebo score @ 8wk0.75% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.52 vs -1.22 placebo score @ 8wk1.5% Cream BID
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.87 vs -0.8 placebo score @ 2wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2 vs -0.8 placebo score @ 2wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.13 vs -1.37 placebo score @ 4wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.91 vs -1.37 placebo score @ 4wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.26 vs -2.08 placebo score @ 8wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.31 vs -2.08 placebo score @ 8wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
PROMIS Sleep-Related Impairment -0.39 score @ 12wk0.75% Cream
absolute change · score
No placebo or comparator arm
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 17 more results
-0.39 score @ 12wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.11 score @ 24wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.02 score @ 24wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.37 score @ 52wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.54 score @ 52wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.73 score @ 12wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.04 score @ 12wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.32 score @ 12wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.04 score @ 12wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.47 score @ 24wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.04 score @ 24wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.11 score @ 24wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.22 score @ 24wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.48 score @ 52wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.33 score @ 52wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.24 score @ 52wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.69 score @ 52wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
PROMIS Sleep Disturbance -0.67 score @ 12wk0.75% Cream
absolute change · score
No placebo or comparator arm
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 17 more results
-0.66 score @ 12wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.02 score @ 24wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.51 score @ 24wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.27 score @ 52wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.07 score @ 52wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2 score @ 12wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.8 score @ 12wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.37 score @ 12wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.32 score @ 12wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.97 score @ 24wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.87 score @ 24wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.03 score @ 24wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.06 score @ 24wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.39 score @ 52wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.88 score @ 52wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.36 score @ 52wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.42 score @ 52wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
BSA -6.84% (n=222) @ 12wk0.75% Cream
absolute change · percentage points
No placebo or comparator arm
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 65 more results
-6.96% (n=225) @ 12wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.36% (n=222) @ 16wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.26% (n=225) @ 16wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.69% (n=222) @ 20wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.49% (n=225) @ 20wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.64% (n=222) @ 24wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.64% (n=225) @ 24wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.66% (n=222) @ 28wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.62% (n=225) @ 28wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.8% (n=222) @ 32wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.61% (n=225) @ 32wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-8.18% (n=222) @ 36wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.97% (n=225) @ 36wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-8.07% (n=222) @ 40wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-8.11% (n=225) @ 40wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-8.14% (n=222) @ 44wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-8.02% (n=225) @ 44wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-8.39% (n=222) @ 48wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.96% (n=225) @ 48wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-8.58% (n=222) @ 52wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-8.14% (n=225) @ 52wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.89% (n=50) @ 12wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-4.71% (n=49) @ 12wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.61% (n=187) @ 12wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.69% (n=203) @ 12wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-4.41% (n=50) @ 16wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-5.47% (n=49) @ 16wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.77% (n=187) @ 16wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.8% (n=203) @ 16wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-4.88% (n=50) @ 20wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.27% (n=49) @ 20wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.48% (n=187) @ 20wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-8.05% (n=203) @ 20wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-4.7% (n=50) @ 24wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.37% (n=49) @ 24wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.49% (n=187) @ 24wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-8% (n=203) @ 24wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-4.59% (n=50) @ 28wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.21% (n=49) @ 28wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.48% (n=187) @ 28wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-8.07% (n=203) @ 28wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-5.1% (n=50) @ 32wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.79% (n=49) @ 32wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.69% (n=187) @ 32wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.89% (n=203) @ 32wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-4.65% (n=50) @ 36wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.16% (n=49) @ 36wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.79% (n=187) @ 36wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-8.38% (n=203) @ 36wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-4.59% (n=50) @ 40wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.42% (n=49) @ 40wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.83% (n=187) @ 40wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-8.44% (n=203) @ 40wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-5.18% (n=50) @ 44wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.56% (n=49) @ 44wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.92% (n=187) @ 44wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-8.43% (n=203) @ 44wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-5.3% (n=50) @ 48wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.61% (n=49) @ 48wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.64% (n=187) @ 48wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-8.33% (n=203) @ 48wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-5.12% (n=50) @ 52wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.83% (n=49) @ 52wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.92% (n=187) @ 52wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-8.42% (n=203) @ 52wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
POEM -10.74 score @ 12wk0.75% Cream
absolute change · score
No placebo or comparator arm
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 17 more results
-11.38 score @ 12wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-10.46 score @ 24wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-11.44 score @ 24wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-10.51 score @ 52wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-10.61 score @ 52wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-5.65 score @ 12wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.04 score @ 12wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-9.72 score @ 12wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-10.58 score @ 12wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-4.03 score @ 24wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-5.71 score @ 24wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-10.3 score @ 24wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-10.58 score @ 24wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.15 score @ 52wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.28 score @ 52wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-10.29 score @ 52wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-10.65 score @ 52wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
DLQI -7.67 score @ 12wk0.75% Cream
absolute change · score
No placebo or comparator arm
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 17 more results
-7.79 score @ 12wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.87 score @ 24wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.75 score @ 24wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.95 score @ 52wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.7 score @ 52wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.09 score @ 12wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.79 score @ 12wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.07 score @ 12wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.06 score @ 12wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.22 score @ 24wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.08 score @ 24wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.17 score @ 24wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.01 score @ 24wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.09 score @ 52wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.2 score @ 52wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.49 score @ 52wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.28 score @ 52wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
CDLQI -5.83 score @ 12wk0.75% Cream
absolute change · score
No placebo or comparator arm
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 17 more results
-8.86 score @ 12wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.72 score @ 24wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-9.42 score @ 24wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.7 score @ 52wk0.75% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-9.71 score @ 52wk1.5% Cream
NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.5 score @ 12wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-4.88 score @ 12wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-5.54 score @ 12wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-5.57 score @ 12wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-8.5 score @ 24wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-4.88 score @ 24wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-5.72 score @ 24wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-5.68 score @ 24wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-8 score @ 52wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.38 score @ 52wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-5.35 score @ 52wk0.75% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.57 score @ 52wk1.5% cream BID
NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3

+ 42 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: baricitinib's landscape · Ruxolitinib (Opzelura)'s landscape